ClinicalTrials.gg
Enrolling by invitationNCT07867808PEMFUpdated Oct 9, 2026

Pulsed Electromagnetic Versus Hydrotherapy on Chronic Pelvic Pain

An interventional study of pulsed electromagnetic field and hydrotherapy in Chronic Pelvic Pain Syndrome, sponsored by Horus University. Enrolling by invitation at 1 site in Jordan. Open to male participants aged 42 Years to 52 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Horus University · Not applicable, Interventional, and Treatment

Updated Oct 9, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
42 Years to 52 Years
Sex
Male
01

Study summary

Pulsed electromagnetic field therapy and hydrotherapy are non-invasive treatment modalities that may alleviate chronic pelvic pain through pain modulation, reduction of inflammation, enhancement of circulation, and relaxation of pelvic musculature. Both interventions have demonstrated potential benefits in reducing pain severity and improving functional outcomes and quality of life in patients with chronic pelvic pain syndrome, supporting their investigation as therapeutic options in clinical research

Read the detailed description

Chronic pelvic pain syndrome is a multifactorial condition characterized by persistent pelvic pain, functional limitations, and impaired quality of life. Pulsed electromagnetic field therapy (PEMF) and hydrotherapy have been proposed as non-pharmacological interventions to address the underlying mechanisms of chronic pain. PEMF may reduce pain by modulating inflammatory responses, enhancing microcirculation, promoting tissue healing, and influencing neural pain pathways. Hydrotherapy may provide therapeutic benefits through the combined effects of warm water, buoyancy, and hydrostatic pressure, leading to muscle relaxation, reduced pelvic floor tension, improved circulation, and enhanced physical function. Previous clinical investigations have demonstrated favorable effects of both interventions on pain intensity, urinary symptoms, functional status, and quality of life in individuals with chronic pelvic pain conditions. Therefore, the combination of PEMF and hydrotherapy may offer a comprehensive therapeutic approach for managing chronic pelvic pain syndrome and improving patient outcomes

02

Conditions studied

  • Chronic Pelvic Pain Syndrome

Browse trials for

Keywords

  • Pulsed Electromagnetic
  • Hydrotherapy
  • Chronic non-bacterial prostatitis
  • pelvic pain
03

In context

Pelvic Pain

387 studies on the registry are indexed under Pelvic Pain; 84 are open to participants now.

This study's planned enrollment of 300 is above the median of 54 across 281 interventional studies indexed under Pelvic Pain.

Browse Pelvic Pain studies →

Lead sponsor

Horus University is the lead sponsor of 33 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
42 Years to 52 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • male patients aged 42 - 50 years
  • chronic non bacterial prostatitis
  • Diagnosis of Chronic Non-Bacterial Prostatitis/Chronic Pelvic Pain Syndrome (NIH Category III) confirmed by a urologist.
  • Presence of pelvic, perineal, suprapubic, testicular, penile, or ejaculatory pain for at least 3 months within the previous 6 months.
  • Stable medical treatment for at least 4 weeks before enrollment, if receiving medications.
  • Ability to understand study procedures and provide written informed consent. Willingness to refrain from initiating new treatments for prostatitis during the study period.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of acute bacterial prostatitis
  • History of prostate cancer, bladder cancer, or other pelvic malignancy
  • Previous prostate surgery within the last 12 months
  • Contraindications to hydrotherapy, including: Open wounds, Active skin infections, Uncontrolled epilepsy, Severe cardiac insufficiency
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Study Group I

    Pulsed electromagnetic field and traditional program in the form of pelvic floor muscle training

    Device: pulsed electromagnetic field · Other: traditional physical therapy program

  • Experimental
    Study Group II

    hydrotherapy and traditional program in the form of pelvic floor muscle training

    Device: hydrotherapy · Other: traditional physical therapy program

  • Experimental
    Control group

    traditional program in the form of pelvic floor muscle training

    Other: traditional physical therapy program

Interventions

  • Devicepulsed electromagnetic field

    Participants allocated to the experimental group will receive pulsed electromagnetic field therapy using a low-frequency PEMF device applied over the suprapubic and perineal regions. Participants will be positioned comfortably in a supine lying position during treatment. The electromagnetic field will be delivered at therapeutic frequencies and intensities according to the manufacturer's recommendations for pain management and soft tissue healing. Each treatment session will last approximately 20-30 minutes, administered three sessions per week for 12 weeks.

  • Devicehydrotherapy

    Participants allocated to the hydrotherapy group will undergo a supervised aquatic exercise program conducted in a therapeutic pool with warm water maintained at 32-34°C. Each session will last approximately 45-60 minutes, three times per week for 12 weeks. The intervention will include gentle warm-up exercises, pelvic mobility exercises, stretching, relaxation techniques, and low-to-moderate intensity aerobic and strengthening activities performed in water.

  • Othertraditional physical therapy program

    The intervention will be administered by a licensed physiotherapist and will consist of pelvic floor muscle awareness training, relaxation exercises, diaphragmatic breathing, stretching exercises, and controlled pelvic floor muscle contractions. Treatment sessions will be conducted three times per week for 12 weeks, with each session lasting approximately 30-45 minutes. Participants will also be instructed to perform a structured home exercise program on non-treatment days

06

What researchers measure

Primary outcomes

  1. chronic pelvic pain

    will be measured by visual analogue scale interpreting pain intensity with minimum score = 0 and maximum score = 10, and lower scores means a better improvement

    Time frame: 12 weeks

Secondary outcomes

  1. participants quality of life

    International consultation on incontinence questionnaire short-form is scored from 0 to 21 points with the lower scores means a better improvement

    Time frame: 12 weeks

07

Study locations

1 site
  • Horus University in Egypt
    Amman, 130, Jordan
08

References and documents

Individual participant data

Plan to share: No — not be shared

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Oct 2026, 3 months after the start.

Of 115 non-industry interventional studies with no phase under Pelvic Pain, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 27. This study's planned 3 months is below that.

Counting every sponsor, half of 119 studies reached it within 17 months; a quarter within 5 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2026
First posted
Oct 9, 2026
StartActual
Jul 20, 2026
Primary completionEst.
Oct 30, 2026
CompletionEst.
Nov 30, 2026
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07867808
Lead sponsor
Horus University
Responsible party
Mohamed Abd El-Naser (Assistant professor of Physical Therapy for Surgery and Burn, Horus University) — Principal investigator
First posted
Oct 9, 2026
Start date
Jul 20, 2026
Primary completion
Oct 30, 2026 (estimated)
Completion
Nov 30, 2026 (estimated)
Last update
Oct 9, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion